Back to top
more

Nuvectis Pharma (NVCT)

(Delayed Data from NSDQ)

$8.14 USD

8.14
55,713

+0.21 (2.65%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $8.16 +0.02 (0.25%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for NVCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Nuvectis Pharma, Inc. [NVCT]

Reports for Purchase

Showing records 1 - 20 ( 103 total )

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/12/2026

Daily Note

Pages: 11

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/11/2026

Company Report

Pages: 6

2025 Results; NXP900 Program Positioned for Multiple Shots on Goal in 2026

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/11/2026

Company Report

Pages: 5

NVCT 4Q25: Several NXP900 Clinical Catalysts Over 2026, Funded Well Into 2H27

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/17/2025

Daily Note

Pages: 4

Phase 1b Study Initiation Marks Next Step for NXP900 Combo Approach

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/03/2025

Daily Note

Pages: 11

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/03/2025

Company Report

Pages: 5

NVCT: KOL Call Highlights NXP900 Results Thus Far And Commercial Opportunity

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/02/2025

Company Report

Pages: 6

NXP900 Poised to Fill the Post-TKI Void; KOL Commentary Reinforces Opportunity

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/04/2025

Company Report

Pages: 8

NXP900 Program Execution on Track With Combo Initiation by YE25; 3Q25 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/04/2025

Daily Note

Pages: 7

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/04/2025

Company Report

Pages: 5

Well Funded Into 3Q27, Prior To Which We Expect Key Clinical Readouts For NXP900

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/28/2025

Daily Note

Pages: 12

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/27/2025

Company Report

Pages: 8

Phase 1a Safety Holds Up as Preclinical Results Support the Phase 1b Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

10/27/2025

Company Report

Pages: 5

Recently Presented Clinical Preclinical NXP900 Data Underscore Its Antitumor Potential

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

09/16/2025

Company Report

Pages: 8

Optimized Entry and Exit Levels for NVCT 091625

Provider: Stock Traders Daily

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/12/2025

Company Report

Pages: 5

Starts Phase 1b Trial With Lead Asset NXP900 In Advanced Solid Tumors

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/12/2025

Company Report

Pages: 6

NXP900 Kicks Off Phase 1b Trial in Genetic Alterations and Resistant NSCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/05/2025

Company Report

Pages: 5

2Q25: Phase 1b Trial For Lead Asset NXP900 Starts Soon, Very Well Funded Into 2H27

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/04/2025

Company Report

Pages: 6

Pipeline Reprioritization Puts NXP900 Front and Center; Price Target Reduced to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/31/2025

Company Report

Pages: 5

Final Phase 1b NXP800 Data in Ovarian Cancer

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Nuvectis Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/08/2025

Company Report

Pages: 8

DDI Study Supports NXP900 as a Combination Agent; Prepping for Phase 1b Initiation

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party